Taro Pharmaceutical Industries (TARO) Rating Increased to Hold at ValuEngine

Taro Pharmaceutical Industries (NYSE:TARO) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Thursday.

A number of other research analysts have also commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $115.00 price objective on shares of Taro Pharmaceutical Industries in a report on Monday, December 10th. Zacks Investment Research raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Thursday, October 11th.

Shares of NYSE TARO opened at $94.62 on Thursday. Taro Pharmaceutical Industries has a one year low of $76.93 and a one year high of $121.23. The firm has a market capitalization of $3.73 billion, a price-to-earnings ratio of 15.31 and a beta of 0.40.



Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings data on Monday, November 5th. The company reported $1.60 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.36). Taro Pharmaceutical Industries had a net margin of 36.33% and a return on equity of 11.99%. The firm had revenue of $158.97 million during the quarter, compared to analyst estimates of $167.40 million. Equities research analysts predict that Taro Pharmaceutical Industries will post 7.4 earnings per share for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in shares of Taro Pharmaceutical Industries during the 3rd quarter worth $689,000. BlueMountain Capital Management LLC grew its holdings in shares of Taro Pharmaceutical Industries by 31.7% during the 3rd quarter. BlueMountain Capital Management LLC now owns 9,271 shares of the company’s stock worth $911,000 after purchasing an additional 2,230 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Taro Pharmaceutical Industries by 15.3% during the 3rd quarter. Renaissance Technologies LLC now owns 331,000 shares of the company’s stock worth $32,537,000 after purchasing an additional 44,000 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Taro Pharmaceutical Industries during the 3rd quarter worth $4,417,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Taro Pharmaceutical Industries during the 3rd quarter worth $315,000. 10.38% of the stock is currently owned by institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Further Reading: What is a put option?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply